Immunogenicity and safety of a tetravalent E. coli O-antigen bioconjugate vaccine in animal models

Vaccine

Volumn 34, Issue 35, 2016, Pages 4152-4160

  van den Dobbelsteen, Germie P J M ^a   Faé, Kellen C ^a   Serroyen, Jan ^a   van den Nieuwenhof, Ingrid M ^a   Braun, Martin ^b   Haeuptle, Micha A ^b,c   Sirena, Dominique ^b   Schneider, Joerg ^b   Alaimo, Cristina ^b   Lipowsky, Gerd ^b   Gambillara Fonck, Veronica ^b   Wacker, Michael ^b,d   Poolman, Jan T ^a  

^a Janssen Research and Development   (Netherlands)

^b LimmaTech Biologics   (Switzerland)

^c MOLECULAR PARTNERS AG   (Switzerland)

^d Wacker Biotech Consulting   (Switzerland)

Author keywords

Conjugate vaccine; Escherichia coli; Extra intestinal pathogenic E. coli (ExPEC); Immunogenicity; Safety; Vaccine

Indexed keywords

ALUMINUM HYDROXIDE; ESCHERICHIA COLI VACCINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; O ANTIGEN; O1 ANTIGEN PSEUDOMONAS EXOTOXIN A CONJUGATE; O2 ANTIGEN PSEUDOMONAS EXOTOXIN A CONJUGATE; O25A ANTIGEN PSEUDOMONAS EXOTOXIN A CONJUGATE; O25B ANTIGEN PSEUDOMONAS EXOTOXIN A CONJUGATE; O6 ANTIGEN PSEUDOMONAS EXOTOXIN A CONJUGATE; PSEUDOMONAS EXOTOXIN; UNCLASSIFIED DRUG; BACTERIAL TOXIN; BACTERIUM ANTIBODY; EXOTOXIN; IMMUNOLOGICAL ADJUVANT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TOXA PROTEIN, PSEUDOMONAS AERUGINOSA; VACCINE; VIRULENCE FACTOR;

ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DRUG CONJUGATION; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL RABBIT; EXTRAINTESTINAL PATHOGENIC ESCHERICHIA COLI; FEMALE; FOOD INTAKE; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; INFLAMMATION; MONONUCLEAR CELL; MOUSE; NO-OBSERVED-ADVERSE-EFFECT LEVEL; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; RAT; SEROTYPE; WEIGHT CHANGE; ANIMAL; BLOOD; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; IMMUNOLOGY; INSTITUTE FOR CANCER RESEARCH MOUSE; LEPORIDAE; SECONDARY IMMUNIZATION; SPRAGUE DAWLEY RAT; TOXICITY TESTING; VACCINE IMMUNOGENICITY;

ADJUVANTS, IMMUNOLOGIC; ADP RIBOSE TRANSFERASES; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL TOXINS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; ESCHERICHIA COLI VACCINES; EXOTOXINS; FEMALE; IMMUNIZATION, SECONDARY; IMMUNOGENICITY, VACCINE; MICE; MICE, INBRED ICR; NO-OBSERVED-ADVERSE-EFFECT LEVEL; O ANTIGENS; RABBITS; RATS; RATS, SPRAGUE-DAWLEY; TOXICITY TESTS; VACCINES, CONJUGATE; VIRULENCE FACTORS;

EID: 84979701665     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.06.067     Document Type: Article

References (47)

1. [1] Croxen, M.A., Finlay, B.B., Molecular mechanisms of Escherichia coli pathogenicity. Nat Rev Microbiol 8 (2010), 26–38, 10.1038/nrmicro2265.
2. [2] Russo, T.A., Johnson, J.R., Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect Inst Pasteur 5 (2003), 449–456.
3. [3] Szijártó, V., Pal, T., Nagy, G., Nagy, E., Ghazawi, A., al-Haj, M., et al. The rapidly emerging ESBL-producing Escherichia coli O25-ST131 clone carries LPS core synthesis genes of the K-12 type. FEMS Microbiol Lett 332 (2012), 131–136, 10.1111/j.1574-6968.2012.02585.x.
4. [4] Zilberberg, M.D., Shorr, A.F., Secular trends in gram-negative resistance among urinary tract infection hospitalizations in the United States, 2000–2009. Infect Control Hosp Epidemiol 34 (2013), 940–946, 10.1086/671740.
5. [5] Hernández, C., Fehér, C., Soriano, A., Marco, F., Almela, M., Cobos-Trigueros, N., et al. Clinical characteristics and outcome of elderly patients with community-onset bacteremia. J Infect 70 (2015), 135–143, 10.1016/j.jinf.2014.09.002.
6. [6] Burns, S.M., Hull, S.I., Comparison of loss of serum resistance by defined lipopolysaccharide mutants and an acapsular mutant of uropathogenic Escherichia coli O75:K5. Infect Immun 66 (1998), 4244–4253.
7. [7] Burns, S.M., Hull, S.I., Loss of resistance to ingestion and phagocytic killing by O(−) and K(−) mutants of a uropathogenic Escherichia coli O75:K5 strain. Infect Immun 67 (1999), 3757–3762.
8. [8] Sarkar, S., Ulett, G.C., Totsika, M., Phan, M.-D., Schembri, M.A., Role of capsule and O antigen in the virulence of uropathogenic Escherichia coli. PLoS ONE, 9, 2014, e94786, 10.1371/journal.pone.0094786.
9. [9] Pluschke, G., Achtman, M., Antibodies to O-antigen of lipopolysaccharide are protective against neonatal infection with Escherichia coli K1. Infect Immun 49 (1985), 365–370.
10. [10] Kim, K.S., Kang, J.H., Cross, A.S., Kaufman, B., Zollinger, W., Sadoff, J., Functional activities of monoclonal antibodies to the O side chain of Escherichia coli lipopolysaccharides in vitro and in vivo. J Infect Dis 157 (1988), 47–53.
11. [11] Schiff, D.E., Wass, C.A., Cryz, S.J., Cross, A.S., Kim, K.S., Estimation of protective levels of anti-O-specific lipopolysaccharide immunoglobulin G antibody against experimental Escherichia coli infection. Infect Immun 61 (1993), 975–980.
12. [12] Poolman, J., Borrow, R., Hyporesponsiveness and its clinical implications after vaccination with polysaccharide or glycoconjugate vaccines. Expert Rev Vaccines 10 (2011), 307–322, 10.1586/erv.11.8.
13. [13] Pollard, A.J., Perrett, K.P., Beverley, P.C., Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nat Rev Immunol 9 (2009), 213–220, 10.1038/nri2494.
14. [14] Mäkelä, P.H., Käyhty, H., Evolution of conjugate vaccines. Expert Rev Vaccines 1 (2002), 399–410, 10.1586/14760584.1.3.399.
15. [15] Weintraub, A., Immunology of bacterial polysaccharide antigens. Carbohydr Res 338 (2003), 2539–2547.
16. [16] Poolman, J.T., Wacker, M., Extraintestinal pathogenic Escherichia coli, a common human pathogen: challenges for vaccine development and progress in the field. J Infect Dis 213 (2015), 6–13, 10.1093/infdis/jiv429.
17. [17] Feldman, M.F., Wacker, M., Hernandez, M., Hitchen, P.G., Marolda, C.L., Kowarik, M., et al. Engineering N-linked protein glycosylation with diverse O antigen lipopolysaccharide structures in Escherichia coli. Proc Natl Acad Sci USA 102 (2005), 3016–3021, 10.1073/pnas.0500044102.
18. [18] Killeen, K.P., Collier, R.J., Conformational integrity of a recombinant toxoid of Pseudomonas aeruginosa exotoxin A containing a deletion of glutamic acid-553. Biochim Biophys Acta 1138 (1992), 162–166.
19. [19] Wacker, M., Wang, L., Kowarik, M., Dowd, M., Lipowsky, G., Faridmoayer, A., et al. Prevention of Staphylococcus aureus infections by glycoprotein vaccines synthesized in Escherichia coli. J Infect Dis 209 (2014), 1551–1561, 10.1093/infdis/jit800.
20. [20] Wacker, M., Linton, D., Hitchen, P.G., Nita-Lazar, M., Haslam, S.M., North, S.J., et al. N-linked glycosylation in Campylobacter jejuni and its functional transfer into E. coli. Science 298 (2002), 1790–1793, 10.1126/science.298.5599.179.
21. [21] Kowarik, M., Young, N.M., Numao, S., Schulz, B.L., Hug, I., Callewaert, N., et al. Definition of the bacterial N-glycosylation site consensus sequence. EMBO J 25 (2006), 1957–1966, 10.1038/sj.emboj.7601087.
22. [22] Olesen, B., Hansen, D.S., Nilsson, F., Frimodt-Møller, J., Leihof, R.F., Struve, C., et al. Prevalence and characteristics of the epidemic multiresistant Escherichia coli ST131 clonal group among extended-spectrum beta-lactamase-producing E. coli isolates in Copenhagen, Denmark. J Clin Microbiol 51 (2013), 1779–1785, 10.1128/JCM.00346-13.
23. [23] Johnson, J.R., Johnston, B., Clabots, C., Kuskowski, M.A., Castanheira, M., Escherichia coli sequence type ST131 as the major cause of serious multidrug-resistant E. coli infections in the United States. Clin Infect Dis 51 (2010), 286–294, 10.1086/653932.
24. [24] Leyva, A., Quintana, A., Sánchez, M., Rodríguez, E.N., Cremata, J., Sánchez, J.C., Rapid and sensitive anthrone-sulfuric acid assay in microplate format to quantify carbohydrate in biopharmaceutical products: method development and validation. Biol J Int Assoc Biol Stand 36 (2008), 134–141, 10.1016/j.biologicals.2007.09.001.
25. [25] Fusco, P.C., Michon, F., Laude-Sharp, M., Minetti, C.A., Huang, C.H., Heron, I., et al. Preclinical studies on a recombinant group B meningococcal porin as a carrier for a novel Haemophilus influenzae type b conjugate vaccine. Vaccine 16 (1998), 1842–1849.
26. [26] Poolman, J.T., Peeters, C.C.A.M., van den Dobbelsteen, G.P.J.M., The history of pneumococcal conjugate vaccine development: dose selection. Expert Rev Vaccines 12 (2013), 1379–1394, 10.1586/14760584.2013.852475.
27. [27] Cross, A., Artenstein, A., Que, J., Fredeking, T., Furer, E., Sadoff, J.C., et al. Safety and immunogenicity of a polyvalent Escherichia coli vaccine in human volunteers. J Infect Dis 170 (1994), 834–840.
28. [28] Peeters, C.C., Tenbergen-Meekes, A.M., Poolman, J.T., Zegers, B.J., Rijkers, G.T., Immunogenicity of a Streptococcus pneumoniae type 4 polysaccharide–protein conjugate vaccine is decreased by admixture of high doses of free saccharide. Vaccine 10 (1992), 833–840.
29. [29] Ahman, H., Käyhty, H., Vuorela, A., Leroy, O., Eskola, J., Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid. Vaccine 17 (1999), 2726–2732.
30. [30] Uehling, D.T., Hopkins, W.J., Dahmer, L.A., Balish, E., Phase I clinical trial of vaginal mucosal immunization for recurrent urinary tract infection. J Urol 152 (1994), 2308–2311.
31. [31] Hopkins, W.J., Elkahwaji, J., Beierle, L.M., Leverson, G.E., Uehling, D.T., Vaginal mucosal vaccine for recurrent urinary tract infections in women: results of a phase 2 clinical trial. J Urol 177 (2007), 1349–1353, 10.1016/j.juro.2006.11.093 quiz 1591.
32. [32] Huber, M., Krauter, K., Winkelmann, G., Bauer, H.W., Rahlfs, V.W., Lauener, P.A., et al. Immunostimulation by bacterial components: II. Efficacy studies and meta-analysis of the bacterial extract OM-89. Int J Immunopharmacol 22 (2000), 1103–1111.
33. [33] Kochiashvili, D., Khuskivadze, A., Kochiashvili, G., Koberidze, G., Kvakhajelidze, V., Role of the bacterial vaccine Solco-Urovac® in treatment and prevention of recurrent urinary tract infections of bacterial origin. Georgian Med News, 2014, 11–16.
34. [34] Lorenzo-Gómez, M.F., Padilla-Fernández, B., García-Criado, F.J., Mirón-Canelo, J.A., Gil-Vicente, A., Nieto-Huertos, A., et al. Evaluation of a therapeutic vaccine for the prevention of recurrent urinary tract infections versus prophylactic treatment with antibiotics. Int Urogynecol J 24 (2013), 127–134, 10.1007/s00192-012-1853-5.
35. [35] Langermann, S., Palaszynski, S., Barnhart, M., Auguste, G., Pinkner, J.S., Burlein, J., et al. Prevention of mucosal Escherichia coli infection by FimH-adhesin-based systemic vaccination. Science 276 (1997), 607–611.
36. [36] Langermann, S., Möllby, R., Burlein, J.E., Palaszynski, S.R., Auguste, C.G., DeFusco, A., et al. Vaccination with FimH adhesin protects cynomolgus monkeys from colonization and infection by uropathogenic Escherichia coli. J Infect Dis 181 (2000), 774–778, 10.1086/315258.
37. [37] MedImmune, Inc. Annual Report 2002. Available at: http://media.corporate-ir.net/media_files/IROL/83/83037/reports/ar02.pdf [Accessed 02.04.15].
38. [38] Cryz, S.J., Cross, A.S., Sadoff, J.C., Fürer, E., Synthesis and characterization of Escherichia coli O18 O-polysaccharide conjugate vaccines. Infect Immun 58 (1990), 373–377.
39. [39] Cryz, S.J., Cross, A.S., Sadoff, J.C., Wegmann, A., Que, J.U., Fürer, E., Safety and immunogenicity of Escherichia coli O18 O-specific polysaccharide (O-PS)-toxin A and O-PS-cholera toxin conjugate vaccines in humans. J Infect Dis 163 (1991), 1040–1045.
40. [40] Ihssen, J., Kowarik, M., Dilettoso, S., Tanner, C., Wacker, M., Thöny-Meyer, L., Production of glycoprotein vaccines in Escherichia coli. Microb Cell Factories, 9, 2010, 61, 10.1186/1475-2859-9-61.
41. [41] Lee, C.J., Quality control of polyvalent pneumococcal polysaccharide-protein conjugate vaccine by nephelometry. Biol J Int Assoc Biol Stand 30 (2002), 97–103.
42. [42] Orskov, I., Orskov, F., Escherichia coli in extra-intestinal infections. J Hyg (Lond) 95 (1985), 551–575.
43. [43] Ananias, M., Yano, T., Serogroups and virulence genotypes of Escherichia coli isolated from patients with sepsis. Braz J Med Biol Res Rev Bras Pesqui Médicas E Biológicas Soc Bras Biofísica Al 41 (2008), 877–883.
44. [44] Molina-López, J., Aparicio-Ozores, G., Ribas-Aparicio, R.M., Gavilanes-Parra, S., Chávez-Berrocal, M.E., Hernández-Castro, R., et al. Drug resistance, serotypes, and phylogenetic groups among uropathogenic Escherichia coli including O25-ST131 in Mexico City. J Infect Dev Ctries 5 (2011), 840–849.
45. [45] Johnson, J.R., Owens, K., Gajewski, A., Kuskowski, M.A., Bacterial characteristics in relation to clinical source of Escherichia coli isolates from women with acute cystitis or pyelonephritis and uninfected women. J Clin Microbiol 43 (2005), 6064–6072, 10.1128/JCM.43.12.6064-6072.2005.
46. [46] Vosti, K.L., A prospective, longitudinal study of the behavior of serologically classified isolates of Escherichia coli in women with recurrent urinary tract infections. J Infect 55 (2007), 8–18, 10.1016/j.jinf.2007.01.006.
47. [47] Schuerman, L., Wysocki, J., Tejedor, J.C., Knuf, M., Kim, K.-H., Poolman, J., Prediction of pneumococcal conjugate vaccine effectiveness against invasive pneumococcal disease using opsonophagocytic activity and antibody concentrations determined by enzyme-linked immunosorbent assay with 22F adsorption. Clin Vaccine Immunol CVI 18 (2011), 2161–2167, 10.1128/CVI.05313-11.